We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
LEGAL & REGULATORY. BMPEA/Acacia rigidula Controversy Fuels Further Criticism of Botanicals.
- Authors
Raterman, Karen
- Abstract
The article addresses the controversy over the U.S. Food and Drug Administration (FDA) ban on marketing and production of products that have the ingredient of Acacia (A) rigidula and beta-methylphenylethylamine (BMPEA). Topics covered include the ban was made after publicized criticism of FDA for not controlling products that have artificial and unapproved stimulant ingredients, and arguments over whether BMPEA is a natural stimulant compound originated from A. rigidula. INSET: Acacia rigidula Herb Profile.
- Subjects
DIETARY supplement laws; AMPHETAMINES; DIETARY supplements; MEDICINAL plants; BOTANIC medicine; PUBLIC health; UNITED States. Food &; Drug Administration; MANUFACTURING industries; GOVERNMENT regulation; STANDARDS
- Publication
HerbalGram, 2015, Issue 107, p60
- ISSN
0899-5648
- Publication type
Article